100827-83-6

Basic information

• Product Name: 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester
• Synonyms: 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester;DesbroMo BrotizolaM 2-Pro;Methyl 2-[4-(2-Chlorophenyl)-9-Methyl-6H-thieno[3,2-f][1,2,4]thiazolo[4,3-a][1,4]diaze- pin-2-yl]ethane-1-carboxylate;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic acid, 4-(2-chlorophenyl)-9-Methyl-, Methyl ester
• CAS NO: 100827-83-6
• Molecular Formula: C₁₉H₁₇ClN₄O₂S
• Molecular Weight: 400.88188
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 100827-83-6.mol

Chemical Properties

• Boiling Point: 595.2°C at 760 mmHg
• Flash Point: 313.7°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 3.93E-14mmHg at 25°C
• Refractive Index: 1.708
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester(100827-83-6)
• EPA Substance Registry System: 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester(100827-83-6)

Safety Data

• Hazardous Substances Data: 100827-83-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester is used as a platelet activating factor antagonist for its potential therapeutic applications in treating conditions related to blood clotting and platelet aggregation. Its ability to antagonize platelet activating factor makes it a promising candidate for the development of drugs targeting cardiovascular and cerebrovascular diseases.
Used in Research Applications:
In addition to its potential pharmaceutical applications, 4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-propanoic Acid Methyl Ester can be utilized in research settings to study the role of platelet activating factor in various physiological and pathological processes. This can contribute to a better understanding of the underlying mechanisms and aid in the discovery of novel therapeutic targets.

InChI:InChI=1/C19H17ClN4O2S/c1-11-22-23-16-10-21-18(13-5-3-4-6-15(13)20)14-9-12(7-8-17(25)26-2)27-19(14)24(11)16/h3-6,9H,7-8,10H2,1-2H3

Upstream product

• 100827-77-8 2-amino-3-(2-carbomethoxyethyl)-6-(2-chlorobenzoyl)thiophene 
• 19515-61-8 diethyl 2-(3-oxo-propyl)malonate 
• 78-39-7 Triethyl orthoacetate 
• 100827-84-7 3-[5-(2-Chloro-phenyl)-2-hydrazono-2,3-dihydro-1H-thieno[2,3-e][1,4]diazepin-7-yl]-propionic acid methyl ester 
• 100827-76-7 diethyl 2-[[5-amino-4-(2-chlorobenzoyl)-thien-2-yl]methyl]malonate 
• 100827-78-9 3-(5-amino-4-(2-chlorobenzoyl)thiophen-2-yl)propionic acid 
• 40018-25-5 2-Chlorobenzoyl acetonitrile 
• 100827-81-4 2-Aminoacetylamino-3-o-chlorobenzoyl-5-(2-carbomethoxyethyl)thiophene 
• 100827-79-0 2-bromoacetylamino-6-(2-carbomethoxyethyl)-3-(2-chlorobenzoyl)thiophene 
• 100827-82-5 7-(2-carbomethoxyethyl)-5-(2-chlorophenyl)-1H-thieno<2,3-e>-1,4-diazepine-2-thione 
• 100827-80-3 7-(2-carbomethoxyethyl)-5-(2-chlorophenyl)-1H-thieno<2,3-e>-1,4-diazepin-2-one 

Downstream Products

• 100826-98-0 2-[4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-ethane-1-carboxylic acid 

Relevant articles and documents

Thieno-1,4-diazepines

The invention relates to new thieno-1,4-diazepines of general formula STR1 wherein R1, R2, R3, R°, R', Z, X, Y and n have the meanings given in the specification. The new compounds are intended to be used in the treatment of pathological conditions and diseases in which PAF (platelet activating factor) is implicated.

Thieno-traizolo-1,4-diazepino-2-carboxylic acid amides

The invention relates to new thieno-traizolo-1,4-diazepino-2-carboxylic acid amides of formula I STR1 wherein R 1 represents hydrogen, a C 1 -C 4 straight-chained or branched alkyl which can optionally be substituted by halogen, preferably Cl or Br, or by hydroxy, cyclopropyl, C 1 -C 3 alkoxy, preferably methoxy, or halogen, preferably chlorine or bromine;R 2 and R 3, each independently, represent hydrogen, a C 1 -C 4 straight-chained or branched alkyl, C 1 -C 4 hydroxyalkyl or the two groups R 2 and R 3 together with the nitrogen atom represent a 5-, 6- or 7-membered ring which optionally contains a nitrogen, oxygen or sulfur atom as a further heteroatom, the second nitrogen atom optionally being substituted by a C 1 -C 4 alkyl, preferably a methyl group;R 4 represents alpha-pyridyl or a phenyl in which the phenyl ring can be substituted preferably in the 2-position, by methyl, halogen, preferably chlorine or bromine, nitro or trifluoromethyl;n represents one of the numbers 0, 1, 2, 3, 4, 5, 6, 7 or 8; and novel intermediates therefor.The compounds of formula I are useful in the treatment of pathological conditions and diseases in which platelet activating factor is implicated.

Brotizolam radioimmunoassay: Development, evaluation, and application to human plasma samples

A radioimmunoassay for the determination of the hypnotic agent brotizolam (11) was developed. With this procedure, an antiserum was used which was obtained from rabbits immunized with the hapten 10 (We 934) covalently bound to serum albumin and tritium-la